Clinical trial intelligence
Explore lessons from European trials — from CTIS timelines and experienced sites to CROs, endpoints and trial design.
1–12 of 205 reports · Page 1 of 18
Compare 38 EU Phase II and III plaque psoriasis studies across recurrent sites, investigators, country footprints, documented CRO support and current recruitment competition.
Read report →Benchmark 31 European Phase III and Phase II/III gastric cancer studies across leading sites, investigators, countries, planned sample sizes and biomarker-driven trial design, with a 19-study first-line subgroup.
Read report →Compare six European Phase III-containing hypertrophic cardiomyopathy studies across recurrent sites, investigators, documented CRO support and current recruitment competition.
Read report →Compare European Phase II and III amyotrophic lateral sclerosis trials across leading sites, recurrent investigators, documented CRO experience and current recruiting competition.
Read report →Compare 12 EU Phase III IgA nephropathy studies across leading sites, investigators, CROs, planned sample sizes and currently recruiting competition.
Read report →Compare 32 European Phase III metastatic colorectal cancer trials across biomarker-defined populations, leading sites, investigators, CROs and countries, including first-line and RAS-mutated findings.
Read report →Benchmark 14 European Phase III-containing topical ophthalmic and eye-drop studies across leading sites, investigators, recruitment plans and CRO support, with a Germany recruitment-feasibility case.
Read report →Compare European Phase III hidradenitis suppurativa and adjacent immune-mediated dermatology trial sites, investigators, country recruitment plans and CRO experience.
Read report →European Phase II and III mitochondrial myopathy trials: leading neurology sites and investigators, clinical assessment patterns, and sonlicromanol findings.
Read report →Benchmark 29 EU Phase III-containing HNSCC trials across sites, investigators, country recruitment plans and CRO support, with focused oropharyngeal and previously treated R/M comparisons.
Read report →Mario Negri and Radboud each appear in five C3G studies. Compare 68 EU sites, 76 investigators and seven Phase II/III trials, with population and extension differences.
Read report →Ghent appears in five of six EU Stargardt studies spanning Phase II, I/II and III. Compare 29 sites, 32 investigators and planned trial sizes.
Read report →We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.
